ClinicalTrials.gg
RecruitingNCT07525583SPICEUpdated Apr 13, 2026

Implementation of Decade of Healthy Ageing Action Plan to Screen and Prevent Decline in Intrinsic Capacity in Elders (SPICE) Through Multisectoral Collaboration in Singapore

An observational study in Frailty, Intrinsic Capacity and Lifestyle, sponsored by National University Hospital, Singapore. Recruiting at 1 site in Singapore. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by National University Hospital, Singapore · Observational

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,500
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Frailty with a site in Singapore — 12 open to participants now, 13 under way, none of them phase 3. Frailty · Singapore.

Started
2025
with 4 others
Observational
7 of 28
3 open now
Primary completion
2027-05
later than 9 of 12 live
Registered
27th of 28
by date
Lead sponsor
3 of 28
National University Hospital, Singapore

Among the 28 studies in Frailty with a site in Singapore, this one is one of 5 that started in 2025, is one of 7 observational ones, reaches primary completion later than 9 of the 12 other live ones, and was the 27th registered.

Frailty

1,291 studies on the registry are indexed under Frailty; 454 are open to participants now.

Browse Frailty studies →

Open to participants now

12 of the 28 studies in Frailty with a site in Singapore are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →

Who these studies take

Of the 299 Frailty studies recruiting now, 235 (79%) set no upper age limit and 10 (3%) stop at 75 or younger; 7 take children under 18; 66 take healthy volunteers.

This study: 60 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Frailty with a site in Singapore, or all of them as a file.
02

Study summary

This study evaluates the implementation of a structured community-based pathway to screen, risk stratify, and prevent decline in intrinsic capacity (IC) among adults aged 60 years and above in Singapore. Using the World Health Organization (WHO) Integrated Care for Older People (ICOPE) framework and digital screening tools, participants will undergo IC domain screening in community settings. Individuals identified with early decline will receive targeted multidomain interventions and/or referral to primary or specialist care as indicated. Participants will be followed longitudinally to assess feasibility, uptake, functional trajectories, and implementation outcomes.

Read the detailed description

Population ageing is associated with progressive decline in intrinsic capacity (IC), defined by WHO as the composite of physical and mental capacities across mobility, cognition, vitality (nutrition), psychological, and sensory domains. Early detection of IC decline enables preventive, person-centred interventions to delay frailty, disability, and long-term care dependency.

The SPICE study operationalises the WHO ICOPE framework within Singapore's community ageing ecosystem through a coordinated hub-and-spoke model linking:Community screening platforms (e.g., Active Ageing Centres), Community Health Posts, Regional health system services and other social service organisations.

The pathway consists of:

Step 1: IC Screening

  • Screening using WHO ICOPE Monitor tools. Step 2: In-Depth Assessment
  • Participants screening positive for decline undergo structured assessment of affected domains.

Step 3: Risk Stratification \& Care Planning

  • Traffic-light classification (low, moderate, high risk) with personalised care plans.

Step 4: Intervention \& Referral

  • Multidomain community interventions (exercise, nutrition, cognitive stimulation, psychosocial engagement) or escalation to medical services when required.

Step 5: Monitoring \& Follow-up

  • Longitudinal follow-up with repeat IC assessments at defined intervals. The study will evaluate implementation feasibility, prevalence of IC decline, adherence to care pathways, functional outcomes, and cost-effectiveness within a real-world community system.

In addition, blood and digital biomarkers will be collected from a subgroup of study participants.

03

Conditions studied

  • Frailty
  • Intrinsic Capacity
  • Lifestyle

Browse trials for

Keywords

  • intrinsic capacity
  • personalized intervention
  • frailty
  • geroscience
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Recruitment will be conducted from Active Ageing Centre and Community Centres.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • pre-frail or robust older adults who can provide consent and follow instructions

Exclusion criteria

Exclusion Criteria:

  • frail or with terminal illness
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,500 participants (estimated)
Patient registry
No

Groups and cohorts

  • Screen and Prevent Intrinsic Capacity Decline in Elders (SPICE)

    Community-dwelling adults robust or pre-frail aged 60 years and above who undergo WHO ICOPE-aligned digital intrinsic capacity screening, structured risk stratification, personalised multidomain community-based interventions, and longitudinal follow-up.

    Other: ICOPE-Based Digital Intrinsic Capacity Monitoring and Triggered Follow-up (SPICE Pathway)

Interventions

  • OtherICOPE-Based Digital Intrinsic Capacity Monitoring and Triggered Follow-up (SPICE Pathway)

    Participants will undergo baseline intrinsic capacity (IC) screening using WHO ICOPE-aligned tools in community settings. Follow-up contacts/visits will occur over the study period and include: 1. Scheduled follow-up at predefined intervals (e.g., every 3, 6-12 months) for repeat IC assessment and outcome data collection; and 2. Triggered (non-scheduled) follow-up that is initiated when remote/digital monitoring indicates decline in one or more IC domains, poor adherence, or when major intercurrent clinical events are reported/identified, prompting in-depth assessment, care plan adjustment, and referral to Community Health Posts, primary care, or specialist services as appropriate.

06

What researchers measure

Primary outcomes

  1. Prevalence of intrinsic capacity decline at baseline (robust / pre-frail)

    Proportion of participants (restricted to robust and pre-frail at baseline) with ≥1 impaired IC domain on screening; and proportion impaired by each domain (mobility, cognition, vitality, psychological, sensory).

    Time frame: Baseline

  2. Uptake of recommended actions (implementation effectiveness)

    Proportion of participants who initiate at least one recommended action within a defined window after screening/plan (e.g., enrolment in a prescribed community programme, completion of recommended assessment, or attendance at a referred service).

    Time frame: Up to 3 months post-recommendation

Secondary outcomes

  1. Identification of (a set of) biomarkers of aging

    Both blood biomarkers and digital markers associated with various intrinsic capacity

    Time frame: 30 months

  2. Feasibility and reach

    Proportion of individuals in each community setting complete both Step 1 and Step 2 assessment.

    Time frame: 30 months

  3. Change in intrinsic capacity and function over time

    Change in number of impaired IC domains (0-5) from baseline to follow-up.

    Time frame: 12 months from enrolment

  4. Frailty progression

    Proportion transitioning from robust → pre-frail/frail; pre-frail → frail

    Time frame: over 12 months follow up

  5. Cost per participant screened

    Programme delivery cost from the provider/programme perspective, calculated as total programme delivery cost divided by the number of participants screened; costs include personnel, training, digital platform/monitoring, screening and assessment delivery, and intervention coordination.

    Time frame: 3 years

  6. Number of participants with at least one unscheduled emergency department visit or hospital admission

    Number and proportion of participants with at least one unscheduled emergency department visit or unplanned hospital admission during follow-up, based on participant report and/or clinical records where available.

    Time frame: 12 months

  7. Implementation outcomes assessed using RE-AIM framework

    Reach: Proportion of eligible older adults screened, characteristics of participants. Effectiveness: Proportion of participants with identified IC impairment who receive recommended follow-up actions, including referral to community services, primary care, or multidisciplinary assessment. Adoption: Provider-reported acceptability and perceived usefulness of the screening pathway (measured using an adapted 8-item questionnaire based on the Theoretical Framework of Acceptability (TFA)). Implementation: Adherence to screening protocols among providers, completion of Step 1 and Step 2 assessments, and referral processes. Implementation strategies, barriers, and facilitators will also be documented by qualitative method. Maintenance: Continued delivery of IC screening at participating sites, and Integration of the programme into routine community health services. The 23-item Normalization Measure Development questionnaire (NoMAD) and the 12-item SCIROCCO tool will be used.

    Time frame: 3 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — It will not be individual level data but rather a group data.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for May 2027, 25 months after the start.

Of 291 non-industry observational studies under Frailty, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 55. This study's planned 25 months is below that.

Counting every sponsor, half of 294 studies reached it within 29 months; a quarter within 12 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2026
First posted
Apr 13, 2026
StartActual
Apr 1, 2025
Primary completionEst.
May 30, 2027
CompletionEst.
Sep 30, 2027
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07525583
Responsible party
Sponsor
First posted
Apr 13, 2026
Start date
Apr 1, 2025
Primary completion
May 30, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Apr 13, 2026

Study contacts

Reshma Merchant (Associate Professor), MBChB (Edin)
Contact
mdcram@nus.edu.sg
+6567724368

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion